Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3375-3379

  Chou, Sunwen ^a,b   Ercolani, Ronald J ^b   Marousek, Gail ^b   Bowlin, Terry L ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c MICROBIOTIX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ANTIVIRUS AGENT; BENZIMIDAVIR; CYCLOPROPAVIR; GANCICLOVIR; IMATINIB; UL97 KINASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANTIVIRAL RESISTANCE; ARTICLE; CATALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME PHOSPHORYLATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG FIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIROGENESIS;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CATALYTIC DOMAIN; CELL LINE; CYCLOPROPANES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; GANCICLOVIR; GENOTYPE; GUANINE; HUMANS; MUTATION; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RIBONUCLEOSIDES;

EID: 84879015973     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00511-13     Document Type: Article

References (33)

1. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A. 2010. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779-785.
2. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M. 2011. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebocontrolled, randomised trial. Lancet Infect. Dis. 11:284-292.
3. Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, Clough L, Avery R, Limaye AP, Ericzon BG, Navasa M, Troisi RI, Chen H, Villano SA, Uknis ME. 2012. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am. J. Transplant. 12:3021-3030.
4. Kern ER, Bidanset DJ, Hartline CB, Yan Z, Zemlicka J, Quenelle DC. 2004. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob. Agents Chemother. 48:4745-4753. (Pubitemid 39577680)
5. Kern ER, Kushner NL, Hartline CB, Williams-Aziz SL, Harden EA, Zhou S, Zemlicka J, Prichard MN. 2005. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob. Agents Chemother. 49:1039-1045. (Pubitemid 40327721)
6. Prichard MN. 2009. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol. 19:215-229.
7. Chou S. 2008. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18:233-246. (Pubitemid 352018847)
8. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712.
9. Chou S, Bowlin TL. 2011. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob. Agents Chemother. 55:382-384.
10. Chou S, Marousek G, Bowlin TL. 2012. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. Antimicrob. Agents Chemother. 56:197-201.
11. Martin M, Goyette N, Ives J, Boivin G. 2010. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J. Clin. Virol. 47:321-324.
12. Martin M, Goyette N, Boivin G. 2010. Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene. J. Clin. Virol. 49:296-298.
13. Eckle T, Prix L, Jahn G, Klingebiel T, Handgretinger R, Selle B, Hamprecht K. 2000. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96:3286-3289.
14. Chou S, Van Wechel LC, Marousek GI. 2007. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 196: 91-94. (Pubitemid 46982742)
15. Chou S, Hakki M, Villano S. 2012. Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. Antiviral Res. 95:88-92.
16. James SH, Hartline CB, Harden EA, Driebe EM, Schupp JM, Engelthaler DM, Keim PS, Bowlin TL, Kern ER, Prichard MN. 2011. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob. Agents Chemother. 55:4682-4691.
17. Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, Van Den Bogaard M, Stamminger T. 2001. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J. Gen. Virol. 82:1439-1450. (Pubitemid 32519775)
18. Michel D, Kramer S, Hohn S, Schaarschmidt P, Wunderlich K, Mertens T. 1999. Amino acids of conserved kinase motifs of cytomegalovirus protein UL97 are essential for autophosphorylation. J. Virol. 73:8898-8901. (Pubitemid 29441761)
19. Michel D, Schaarschmidt P, Wunderlich K, Heuschmid M, Simoncini L, Muhlberger D, Zimmermann A, Pavic I, Mertens T. 1998. Functional regions of the human cytomegalovirus protein pUL97 involved in nuclear localization and phosphorylation of ganciclovir and pUL97 itself. J. Gen. Virol. 79:2105-2112. (Pubitemid 28423404)
20. Chou S. 2010. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob. Agents Chemother. 54:2371-2378.
21. Chou S, Van Wechel LC, Lichy HM, Marousek GI. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49: 2710-2715. (Pubitemid 40917582)
22. Becke S, Fabre-Mersseman V, Aue S, Auerochs S, Sedmak T, Wolfrum U, Strand D, Marschall M, Plachter B, Reyda S. 2010. Modification of the major tegument protein pp65 of human cytomegalovirus inhibits virus growth and leads to the enhancement of a protein complex with pUL69 and pUL97 in infected cells. J. Gen. Virol. 91:2531-2541.
23. Prichard MN, Britt WJ, Daily SL, Hartline CB, Kern ER. 2005. Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J. Virol. 79:15494-15502. (Pubitemid 43032331)
24. Chou S, Van Wechel LC, Marousek GI. 2006. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob. Agents Chemother. 50:2557-2559. (Pubitemid 43993205)
25. Hanks SK, Quinn AM, Hunter T. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42-52.
26. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G. 2006. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphiapositive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12:7374-7379. (Pubitemid 46095411)
27. Diamond JM, Melo JV. 2011. Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk. Lymphoma 52(Suppl 1):12-22.
28. Shannon-Lowe CD, Emery VC. 2010. The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae 1:4.
29. Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, Rostaing L, Saint Marcoux F, Essig M, Rerolle JP, Cotin S, Germi R, Pillet S, Lebranchu Y, Turlure P, Alain S. 2010. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J. Antimicrob. Chemother. 65:2628-2640.
30. Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, Ives J, Hartmann A, Humar A. 2009. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir. Ther. 14:697-704.
31. Chou S, Marousek G, Boivin G, Goyette N, Farhan M, Ives JA, Elston R. 2010. Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Transplantation 90:1409-1413.
32. Chou S, Marousek GI, Van Wechel LC, Li S, Weinberg A. 2007. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob. Agents Chemother. 51:4160-4162. (Pubitemid 350057819)
33. Boivin G, Goyette N, Farhan M, Ives J, Elston R. 2012. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J. Clin. Virol. 53:208-213.